Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Phio Pharmaceuticals Corp.PHIO · Entity 7889 | Director | September 28, 2026 | September 30, 2026 |
| Timber Pharmaceuticals, Inc.BPMX · Entity 110330 | Director | June 12, 2019 | June 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Phio Pharmaceuticals Corp.
Report date September 28, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.0001 par valueSEC Table I · non-derivative | Direct | 42,000 |
Last balance in matching sequence
After 2026-09-29 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-09-28 · Purchase · Acquired 5,000 · Balance 37,000 F1: Includes shares of common stock underlying unvested restricted stock units. Row 2 · 2026-09-29 · Purchase · Acquired 5,000 · Balance 42,000 F1: Includes shares of common stock underlying unvested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares of common stock underlying unvested restricted stock units.
Timber Pharmaceuticals, Inc.
Report date June 12, 2019 · Filed June 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2029-06-12 | Direct | 32,700 |
Reported balance
After 2019-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-12 · Grant · Acquired 32,700 · Balance 32,700 F1: This option vests ratably over 12 months starting on 7/12/2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests ratably over 12 months starting on 7/12/2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2026 Filed Sep 30, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 5,000 | $1.04 | $5,200.00 |
DisclosureSEC source: 0001683168-26-007499 · ownership.xml · nonDerivative · entry 2 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 28, 2026 Filed Sep 30, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 5,000 | $1.03 | $5,150.00 |
DisclosureSEC source: 0001683168-26-007499 · ownership.xml · nonDerivative · entry 1 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 F1 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| September 28, 2026 Filed Sep 29, 2026 20:01 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | GrantCommon Stock, $.0001 par value | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-007482 · ownership.xml · nonDerivative · entry 1 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. F2 · balance_after: Includes shares of common stock underlying unvested restricted stock units. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 12:30 UTC | Phio Pharmaceuticals Corp. PHIO · Entity 7889 | PurchaseCommon Stock, $.0001 par value | 15,000 | $1.14 | $17,100.00 |
DisclosureSEC source: 0001683168-26-006620 · ownership.xml · nonDerivative · entry 1 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 16:44 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 32,700 | $0.84 Strike: $0.84 | $27,468.00 |
DisclosureSEC source: 0001424422-19-000006 · primary_doc.xml · derivative · entry 1 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,700 Underlying: Common stock · 32,700 shares Expires 2029-06-12 F1 · security: This option vests ratably over 12 months starting on 7/12/2019. Read SEC document |
| February 01, 2019 Filed Feb 21, 2019 18:35 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 51,000 | $0.20 Strike: $0.20 | $10,200.00 |
DisclosureSEC source: 0001424422-19-000003 · primary_doc.xml · derivative · entry 4 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 418,000 Underlying: Common stock · 51,000 shares Expires 2029-02-01 F2 · security: This option vests ratably over 24 months with the first vesting starting on 3/1/2019. Read SEC document |
| February 01, 2019 Filed Feb 21, 2019 18:35 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 34,000 | $0.20 Strike: $0.20 | $6,800.00 |
DisclosureSEC source: 0001424422-19-000003 · primary_doc.xml · derivative · entry 3 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,000 Underlying: Common stock · 34,000 shares Expires 2029-02-01 F1 · security: This option vests ratably over 4 months with the first vesting starting on 3/1/2019. Read SEC document |
| February 01, 2019 Filed Feb 21, 2019 18:35 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 200,000 | $0.11 Strike: $0.11 | $22,000.00 |
DisclosureSEC source: 0001424422-19-000003 · primary_doc.xml · derivative · entry 2 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,000 Underlying: Common stock · 200,000 shares Expires 2029-02-01 F2 · security: This option vests ratably over 24 months with the first vesting starting on 3/1/2019. Read SEC document |
| February 01, 2019 Filed Feb 21, 2019 18:35 UTC | Timber Pharmaceuticals, Inc. BPMX · Entity 110330 | GrantOption to purchase common stock · Derivative | 133,000 | $0.11 Strike: $0.11 | $14,630.00 |
DisclosureSEC source: 0001424422-19-000003 · primary_doc.xml · derivative · entry 1 Plott Ronald Todd · CIK 0001768337 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,000 Underlying: Common stock · 133,000 shares Expires 2029-02-01 F1 · security: This option vests ratably over 4 months with the first vesting starting on 3/1/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.